Cell News and Research

RSS

Inhibition of PBEF could be potential therapeutic target for pulmonary hypertension

Inhibition of pre-B Cell Colony-Enhancing Factor (PBEF) could be a potential therapeutic target for pulmonary hypertension (PH), according to a preclinical study in an animal model of PH.

23 May 2012

EMBO Journal highlights three decades of Wnt research

The impact and influence of thirty years of research into the Wnt/beta-catenin signaling pathway are highlighted in a special issue of The EMBO Journal.

23 May 2012

IntelliCell enters sponsored research agreement with ICERM

IntelliCell BioSciences, Inc. announced today that it has entered a sponsored research agreement with the Institute for Cell Engineering and Regenerative Medicine (ICERM) at the University of Florida.

23 May 2012

Scientists develop new type of anti-cancer drug

A team of University of Hawaii Cancer Center scientists led by James Turkson, Ph.D. have created a new type of anti-cancer drug named BP-1-102. The drug, which can be orally administered, targets a key protein that triggers the development of many types of cancer including lung, breast and skin cancers.

23 May 2012

Botch protein appears to play an important regulatory role in forming neurons, other cell types

Johns Hopkins scientists have discovered a protein that appears to play an important regulatory role in deciding whether stem cells differentiate into the cells that make up the brain, as well as countless other tissues.

23 May 2012

GE Healthcare, KUH partner to drive advances in cell therapy technologies

Karolinska University Hospital Sweden and GE Healthcare Life Sciences today announced a joint research collaboration to drive advances in technologies and workflows for use in the rapidly emerging field of cell therapy.

22 May 2012

Researchers to create new type of bioactive coating for brain aneurysm stents

Researchers at Purdue University are working with the U.S. Army and neurosurgeons at the Walter Reed National Military Medical Center to create a new type of "bioactive" coating for stents used to treat brain aneurysms including those caused by head trauma from bomb blasts.

22 May 2012

Diamyd Medical completes enrollment in NP2 Enkephalin Phase II study for cancer pain

The last study participant has been recruited to Diamyd Medical's Phase II study in which cancer pain is treated with the drug candidate NP2 Enkephalin. The study is thus fully enrolled and results are expected to be reported in five to seven weeks.

22 May 2012

Bayer’s Nexavar Phase 3 trial on NSCLC does not meet primary endpoint

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial evaluating Nexavar (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.

22 May 2012

Airway inflammation linked with asthma-related mortality rates in older adults

Higher mortality rates among older adult asthma patients compared to their younger counterparts may be due, at least in part, to an increase in airway inflammation, according to a study conducted by researchers in Canada, who note that their results imply that elderly patients are either less likely to follow asthma medication dosing instructions, or that the underlying airway inflammation in elderly patients is relatively resistant to current anti-inflammatory therapies.

22 May 2012

Enrollment complete in Xencor, MorphoSys’ MOR208 phase 1 trial for CLL

MorphoSys AG and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.

22 May 2012

TransCytos, Enginasion collaborate to develop new transfection technology

Enginasion and TransCytos announced today that their collaboration has resulted in a prototype 'transfection' technology that is designed to have a dramatic and positive impact on the drug-research industry.

22 May 2012

HSF-1 protein likely source of chemotherapy-related heart damage in mice

Blocking a protein in the heart that is produced under stressful conditions could be a strategy to prevent cardiac damage that results from chemotherapy, a new study suggests.

22 May 2012

Some patients appear to be more predisposed for recurrent infection from C. diff

University of Cincinnati (UC) researchers have found that some patients appear to be more predisposed for recurrent infection from the bacterium Clostridium difficile, or C. diff, and that it may advance to a more serious inflammatory condition in those individuals.

22 May 2012

VEN occurs also in the insula of macaque monkeys

The anterior insular cortex is a small brain region that plays a crucial role in human self-awareness and in related neuropsychiatric disorders. A unique cell type - the von Economo neuron (VEN) - is located there. For a long time, the VEN was assumed to be unique to humans, great apes, whales and elephants.

22 May 2012

Scientists unravel action mechanism of castor oil

Castor oil is known primarily as an effective laxative; however, it was also used in ancient times with pregnant women to induce labour. Only now have scientists at the Max Planck Institute for Heart and Lung Research succeeded in unravelling the mysteries of the action mechanism. A receptor by the name of EP3 on the cells of the intestine and uterus is apparently responsible. This is activated by an ingredient in the oil.

22 May 2012

T cell imbalance may put certain people at increased risk of C. difficile infection

University of Cincinnati (UC) researchers have found that an imbalance in the regulation of certain T cells-the cells in the body that fight off infection or attack the system in certain autoimmune diseases-may put certain people at a higher risk of having recurrent cases of Clostridium difficile, or C. Diff, infection.

22 May 2012

CHDI, Lundbeck enter collaboration to investigate targeted therapy for Huntington's disease

CHDI Foundation, Inc. and Lundbeck today announced a research collaboration to investigate a targeted therapy for Huntington's disease (HD). Currently, no treatment exists to slow or halt the progression of HD, a challenging hereditary neurodegenerative disease characterized by a triad of behavioral, cognitive, and motor symptoms.

21 May 2012

Large neurological problems could be addressed through changing Botch activity

21 May 2012

Opexa's Tovaxin for MS is now Tcelna

Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company is rebranding its leading MS therapy with the new name Tcelna. The product, previously known as Tovaxin, will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).

21 May 2012